Predictors of Survival and Disease-Free Survival in Patients With Resected N1 Non-Small Cell Lung Cancer

Annals of Thoracic Surgery

Volumn 84, Issue 1, 2007, Pages 182-190

  Cerfolio, Robert J ^a   Bryant, Ayesha S ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THORAX SURGERY; TUMOR DIFFERENTIATION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250369709     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.03.030     Document Type: Article

References (21)

1. Mountain C.F. The international system for staging lung cancer. Semin Surg Oncol 18 (2000) 106-115
2. Fujimoto T., Cassivi S.D., Yang P., et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg 132 (2006) 499-506
3. Bryant A.S., Cerfolio R.J., Klemm K.M., and Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82 (2006) 417-422
4. Cerfolio R.J., and Bryant A.S. Survival and outcomes of pulmonary resection of non-small cell lung cancer in the elderly: a nested case control study. Ann Thorac Surg 82 (2006) 424-430
5. Hawes R.H., Gress F., Kesler K.A., Cummings O.W., and Conces Jr. D.J. Endoscopic ultrasound versus computed tomography in the evaluation of the mediastinum in patients with non-small-cell lung cancer. Endoscopy 26 (1994) 784-787
6. Cerfolio R.J., Bryant A.S., Ojha B., and Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 80 (2005) 1207-1213
7. Oda M., Watanabe Y., Shimizu J., et al. Extent of mediastinal node metastasis in clinical stage I non-small-cell lung cancer: the role of systematic nodal dissection. Lung Cancer 22 (1998) 23-30
8. Cerfolio R.J., Ojha B., Bryant A.S., Bass C.S., Bartalucci A.A., and Mountz J.M. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 76 (2003) 861-866
9. Vansteenkiste J.F., and Mortelmans L.A. FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A comprehensive review of the Leuven Lung Cancer Group Experience. Clin Positron Imaging 2 (1999) 223-231
10. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
11. Halter G., Buck A.K., Schirrmeister H., et al. Lymph node staging in lung cancer using FDG-PET. Thorac Cardiov Surg 52 (2004) 96-101
12. Cerfolio R.J., Ojha B., Bryant A.S., Raghuveer V., Mountz J.M., and Bartolucci A.A. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78 (2004) 1017-1023
13. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
14. Osaki T., Nagashima A., Yoshimatsu T., Tashima Y., and Yasumoto K. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 43 (2004) 151-157
15. Tanaka F., Yanagihara K., Otake Y., et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 19 (2001) 555-561
16. Riquet M., Manac'h D., Le P.-b., Dujon A., and Chehab A. Prognostic significance of surgical-pathological N1 disease in non-small cell lung carcinoma of the lung. Ann Thorac Surg 67 (1999) 1573-1576
17. van Velzen E., Snijder R.J., Brutel de la Riviere A., Elbers H.J., and van den Bosch J.M. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Chest 110 (1996) 1469-1473
18. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
19. Winton T., Livingston R., Johnson D., et al. Vinorelbine and cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
20. Douillard J., Rousell R., Delena M., et al. ANITA: phase III adjuvant vimorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts); final results after 70-month median follow-up [abstract]. Proc Am Soc Clin Oncol 24 (2005) 619
21. Pisters K.M., Kris M.G., Gralla R.J., Zaman M.B., Heelan R.T., and Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11 (1993) 1757-1762